We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Key Gene Identified in Common Heart Disease Unlocks Life-Saving Diagnostic Potential

By LabMedica International staff writers
Posted on 24 Apr 2025

Hypertrophic cardiomyopathy (HCM) is the most prevalent hereditary heart disease globally, affecting approximately 1 in 200 individuals, and remains a leading cause of heart transplantation. More...

Many people with HCM are unaware they have the condition until symptoms manifest, often when the disease has already progressed to a more severe stage. Now, a groundbreaking study has identified TRIM63 as a significant genetic factor contributing to HCM. The findings, published in Circulation: Genomic and Precision Medicine, have the potential to revolutionize genetic screening and treatment protocols for HCM patients worldwide.

The study, conducted by researchers at Clalit Research Institute (Ramat-Gan, Israel), provides compelling evidence of the gene’s role in both the causation and increased susceptibility to HCM. The researchers analyzed 107 unrelated HCM patients using advanced exome-based gene panels, focusing on diverse populations such as Ashkenazi Jews, Muslim Arabs, and North African and Middle Eastern Jewish communities. The study found biallelic (two-copy) pathogenic TRIM63 variants in 4.7% of the patients, accounting for 18.5% of all genetic diagnoses in the cohort. These patients displayed early-onset, severe heart muscle thickening, frequent arrhythmias, and recurrent fainting episodes, with some requiring implantable defibrillators (ICDs) before receiving their genetic diagnosis. Additionally, monoallelic (single-copy) pathogenic variants were identified in 7.5% of patients. Compared to a non-cardiac control group, these variants were found to be 8.2 times more common in HCM patients, strongly suggesting that even one faulty copy of TRIM63 significantly increases the risk of developing HCM.

The study also uncovered a previously undocumented mutation (c.277C>T), which was notably common among individuals of Libyan Jewish descent, with an estimated disease frequency of 1 in 14,400. This highlights the importance of targeted screening in genetically isolated or consanguineous populations. Despite accumulating evidence, TRIM63 is still absent from many commercial HCM gene panels, primarily due to historical uncertainty surrounding its role in the disease. This new research provides compelling evidence to include TRIM63 in diagnostic protocols, especially in high-risk or underrepresented populations. The study also emphasizes the benefits of exome-based genetic testing, which allows for continuous reanalysis and the easy inclusion of newly validated genes, offering far more flexibility than traditional static, gene-specific panels.

“This is a life-saving discovery. Recognizing carriers of disease-causing TRIM63 mutations enables early monitoring and intervention, dramatically lowering the risk of severe, even fatal, cardiac events,” said Dr. Ruhrman Shahar who led the study. “Our findings represent a major step forward in cardiac genetics. This mutation causes severe cardiomyopathy and should be recognized as a key risk factor for heart dysfunction. We believe these insights will impact millions worldwide, both in diagnosis and in care.”


New
Gold Member
Latex Test
SLE-Latex Test
Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
New
Giardia Assay
AccuDiag Giardia
New
HAV Rapid Test
OnSite HAV IgG/IgM Rapid Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: Custom hardware and software for the real-time detection of immune cell biophysical signatures in NICU (Photo courtesy of Pediatric Research, DOI:10.1038/s41390-025-03952-y)

First-Of-Its-Kind Device Profiles Newborns' Immune Function Using Single Blood Drop

Premature infants are highly susceptible to severe and life-threatening conditions, such as sepsis and necrotizing enterocolitis (NEC). Newborn sepsis, which is a bloodstream infection occurring in the... Read more

Pathology

view channel
Image: The innovative doublet configuration and annular illumination overcome traditional metalens limitations (Photo courtesy of Tao Li and Jiacheng Sun/Nanjing University)

High-Resolution Metalens Doublet Microscope to Enhance Diagnostic Capabilities

Metalenses mark a groundbreaking leap in optical technology. Unlike traditional microscope objectives that rely on curved glass surfaces, metalenses utilize nanoscale structures to manipulate light at... Read more

Technology

view channel
Image: Concept of biosensor integrated into hygiene pads enabling direct semi-quantitative analysis of biomarkers in unprocessed menstruation blood (Photo courtesy of Dosnon, L et al. DOI: 10.1002/advs.202505170)

First Ever Technology Recognizes Disease Biomarkers Directly in Menstrual Blood in Sanitary Towels

Over 1.8 billion people menstruate worldwide, yet menstrual blood has been largely overlooked in medical practice. This blood contains hundreds of proteins, many of which correlate with their concentration... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.